Preclinical investigation of patient- derived cervical cancer organoids for precision medicine

설향숙; 오주희; 최은혜; 김상민; 김현기; Eun Ji Nam

doi:10.3802/jgo.2023.34.e35

추천

검색

자료유형: 학술저널

저자정보: 설향숙 (Yonsei University College of Medicine Seoul Korea) 오주희 (Yonsei University College of Medicine Seoul Korea) 최은혜 (Yonsei University College of Medicine Seoul Korea) 김상민 (Yonsei University College of Medicine Seoul Korea) 김현기 (Yonsei University College of Medicine Seoul Korea) Eun Ji Nam (Institute of Women)

저널정보: 대한부인종양학회 Journal of Gynecologic Oncology Journal of Gynecologic Oncology Vol.34 No.3

발행연도: 2023.5

수록면: 1 - 14 (14page)

DOI: 10.3802/jgo.2023.34.e35

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: Advanced cer vical cancer is still difficult to treat and in the case of recurrentcancer, it is desirable to utilize personalized treatment rather than uniform treatmentbecause the type of recurrence is different for each individual. Therefore, this studyaimed to establish a patient-derived organoid (PDO) platform to determine the effects ofchemotherapy, radiation therapy, and targeted therapy in cer vical cancer. Methods: We established organoids from 4 patients with various types of cer vical cancer. Thehistopathological and gene profiles of these organoid models were compared to determinetheir characteristics and the maintenance of the patient phenotype. Each type of organoid wasalso subjected to anticancer drug screening and radiation therapy to evaluate its sensitivity. Results: We established PDOs to recapitulate the main elements of the original patienttumors, including the DNA copy number and mutational profile. We selected 7 drugsthat showed growth inhibition in cer vical cancer organoids out of 171 using an Food andDrug Administration -approved drug librar y. Moreover, adenocarcinoma and large-cellneuroendocrine carcinoma showed resistance to radiation therapy. whereas squamous cellcarcinoma and villoglandular carcinoma showed a significant response to radiotherapy. Conclusion: Our results showed that patient-derived cer vical cancer organoids can be usedas a platform for drug and radiation sensitivity testing. These findings suggest that patient-derived cer vical cancer organoids could be used as a personalized medicine platform and mayprovide the best treatment options for patients with various subtypes of cer vical cancer.

#Keywords: Organoids #Cer vical Cancer #Radiation #Tumor-Specific Drug Screening Tests

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!